The Psychedelic Lineage
Ancient ceremony, modern science, and the return of non-ordinary states to clinical practice
Clinical and evidence statements in this lineage remain under review. The source checks below apply only to their stated treatment, population and outcome.
Guideline sources for approaches in this lineage
KAP
Guidelines and official sources (7)
6 clinical guideline checks · 1 regulatory source check
Read the recommendation and its scope. A source may discuss an approach without recommending it.
- SPRAVATO (esketamine) original prescribing information
Not a treatment recommendation
The historical drug indication is verified. It does not establish approval or guideline endorsement of KAP. This original label is not current prescribing information.
Scope: Esketamine nasal spray plus an oral antidepressant for adult TRD in 2019
- Management of Major Depressive Disorder
Discussed in the source
VA/DoD weakly suggests ketamine or esketamine augmentation. The recommendation concerns medication, not a named KAP psychotherapy protocol.
Scope: MDD after several adequate pharmacological trials have failed
- Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder
Discussed in the source
VA/DoD weakly recommends against ketamine for PTSD. The statement concerns medication and does not separately evaluate KAP.
Scope: Ketamine pharmacotherapy for adult PTSD; not a separate KAP psychotherapy assessment.
- Assessment and Management of Patients at Risk for Suicide
Discussed in the source
VA/DoD weakly supports ketamine infusion for short-term ideation reduction; evidence for preventing attempts or suicide is insufficient. KAP is not separately recommended.
Scope: Adjunctive ketamine infusion in adults aged 18 and over with major depression and suicidal ideation; medication rather than KAP psychotherapy.
- Management of Major Depressive Disorder
Discussed in the source
VA/DoD suggests against ketamine/esketamine as initial pharmacotherapy (weak against). Its separate augmentation recommendation concerns prior treatment failure; neither recommendation endorses a named KAP psychotherapy protocol.
Scope: Adults choosing initial medication treatment for MDD.
- Management of Bipolar Disorder
Discussed in the source
VA/DoD finds insufficient evidence for ketamine/esketamine alone or as adjuncts. The recommendation concerns medication and does not endorse KAP psychotherapy.
Scope: Adults with acute bipolar depression.
- Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder in Adults
Discussed in the source
APA reports insufficient evidence for ketamine in these comparisons. This is a drug-level finding, not a separate evaluation of the KAP psychotherapy protocol.
Scope: Adults with PTSD; ketamine compared with an active or inactive intervention.
MDMA-Assisted Therapy
Guidelines and official sources (4)
3 clinical guideline checks · 1 regulatory source check
Read the recommendation and its scope. A source may discuss an approach without recommending it.
- NDA 215455: midomafetamine complete response letter
Not a treatment recommendation
The letter verifies the 2024 nonapproval decision and identifies safety reporting, durability and bias concerns. Psychotherapy-contribution questions appear separately as additional comments.
Scope: Midomafetamine application NDA 215455 for PTSD
- Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder
Insufficient evidence for or against
VA/DoD finds insufficient evidence for or against MDMA-assisted psychotherapy. The guideline’s evidence cutoff precedes later trials and regulatory decisions.
Scope: MDMA-assisted psychotherapy for adults with PTSD; evidence reviewed through May 2022.
- Management of Major Depressive Disorder
Recommendation against the stated use
VA/DoD strongly recommends against MDMA for MDD outside research. This 2022 guideline used evidence through January 2021; it does not assess later trials or every diagnosis.
Scope: MDMA for MDD outside research settings.
- Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder in Adults
Insufficient evidence for or against
APA finds insufficient evidence for or against this intervention in the reviewed comparisons.
Scope: Adults with PTSD; MDMA-assisted psychotherapy versus the inactive or low-dose active comparators reviewed.
Psilocybin-Assisted Therapy
Guidelines and official sources (3)
2 clinical guideline checks · 1 regulatory source check
Read the recommendation and its scope. A source may discuss an approach without recommending it.
- FDA accelerates action on treatments for serious mental illness following Executive Order
Not a treatment recommendation
FDA announced priority vouchers for psilocybin studies in April 2026. This establishes development activity, not approval or psychotherapy endorsement.
Scope: Companies studying psilocybin for TRD and MDD
- Management of Major Depressive Disorder
Recommendation against the stated use
VA/DoD strongly recommends against psilocybin for MDD outside research. This 2022 guideline used evidence through January 2021 and does not review subsequent trials.
Scope: Psilocybin for MDD outside research settings
- Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder
Discussed in the source
VA/DoD finds insufficient evidence for or against psilocybin for PTSD. The statement does not separately establish a psychotherapy-protocol recommendation.
Scope: Psilocybin pharmacotherapy for adult PTSD; evidence reviewed through May 2022.
Humans have used psychoactive substances for healing and spiritual transformation for millennia. The modern clinical lineage begins with Albert Hofmann's synthesis of LSD in 1938, and the first wave of research (1950s–60s) that produced over a thousand published papers and remarkable clinical results for alcoholism, depression, and end-of-life anxiety. The backlash — driven by cultural panic, the counterculture, and political pressure — shut research down for decades. The renaissance, beginning in the late 1990s at Johns Hopkins, NYU, Imperial College London, and MAPS, has produced some of the most striking results in contemporary psychiatry. This lineage raises fundamental questions about consciousness, healing, and the relationship between pharmacology and psychotherapy.
Full Contents
Read all 11 entries as a single page
-
Indigenous & Ancient Use
Psilocybin mushrooms, ayahuasca, peyote, iboga, San Pedro cactus, and other plant medicines have been used in indigenous ceremonial contexts for thousands of years — for healing, divination, initiation, and spiritual communion. These are not "preclinical" uses; they are sophisticated healing technologies with their own frameworks.
Concepts: Set and setting (indigenous origins) · Ceremony and container · Plant teachers / plant spirits · Community integration · Initiation and transformation
-
William James & Aldous Huxley
James's "Varieties of Religious Experience" (1902) legitimized the study of mystical and altered states within academic psychology. Huxley's "The Doors of Perception" (1954) — his account of mescaline — brought psychedelic experience into intellectual discourse. Both argued that ordinary waking consciousness is only one type of consciousness among many.
Concepts: Varieties of religious experience · The doors of perception · Mystical experience · Perennial philosophy · Reducing valve theory of consciousness
Relation: James and Huxley provided the philosophical legitimacy for taking altered states seriously. James's pragmatism asked: if the experience transforms the person, does the mechanism matter? This question remains central to the field.
-
Albert Hofmann & LSD
Synthesized LSD-25 at Sandoz in 1938; discovered its psychoactive properties through accidental exposure in 1943. Called it his "problem child." Hofmann viewed LSD as a tool for consciousness research and spiritual exploration, not recreational use.
Concepts: LSD (lysergic acid diethylamide) · Bicycle Day (April 19, 1943) · Psychotomimetic model (early — LSD mimics psychosis) · Consciousness research tool
-
Stanislav & Christina Grof / Holotropic Breathwork
When LSD became illegal, Grof developed Holotropic Breathwork — using accelerated breathing, evocative music, and bodywork to access non-ordinary states without substances. Based on decades of LSD research, it preserved the cartography of inner experience while making it legally accessible.
Concepts: Holotropic states · COEX systems · Perinatal matrices · Transpersonal experiences · Inner healing intelligence · Mandala drawing
Relation: Grof bridges the first wave and the renaissance. His experiential maps — biographical, perinatal, and transpersonal domains — inform how many contemporary therapists understand psychedelic experiences. Holotropic Breathwork kept the clinical knowledge alive during prohibition.
-
First Wave Research
Over 1,000 papers published. Two models emerged: psycholytic (low-dose, multiple sessions, psychodynamic framework — European) and psychedelic (high-dose, single transformative experience — North American). Remarkable results for alcoholism, end-of-life anxiety, and depression. Grof mapped the phenomenology of non-ordinary states across thousands of sessions.
Concepts: Psycholytic vs. psychedelic therapy · Perinatal matrices (Grof) · Systems of Condensed Experience (COEX) · Transpersonal experiences · Ego dissolution
Relation: The first wave showed extraordinary clinical potential but lacked methodological rigor by today's standards (no randomization, limited controls). Grof's work was the most systematic — his maps of psychedelic experience remain influential even as the field moves toward manualized protocols.
-
The Shutdown
LSD became a symbol of the counterculture. Leary's "turn on, tune in, drop out" terrified the establishment. Scheduling of LSD (1970), psilocybin, mescaline, and later MDMA (1985) effectively ended clinical research for decades. The scientific baby was thrown out with the countercultural bathwater.
Concepts: Schedule I classification · Moral panic · Loss of research infrastructure · Underground therapy continued · MAPS founded (1986)
Relation: The shutdown was political, not scientific. The research evidence was promising; the cultural context was threatening. Rick Doblin founded MAPS in 1986 specifically to navigate the regulatory path back to legal psychedelic therapy — a project that took 35 years.
-
MAPS & MDMA-Assisted Therapy
MAPS (Multidisciplinary Association for Psychedelic Studies) spent 35 years navigating the regulatory path for MDMA-assisted therapy for PTSD. Phase 3 trials showed unprecedented effect sizes. MDMA enhances empathy, reduces fear, and opens a therapeutic window for trauma processing. FDA advisory committee review in 2024 was controversial.
Concepts: MDMA as empathogen · Inner healing intelligence · Therapeutic window · Three preparatory + three medicine + nine integration sessions · Non-directive support
Relation: MDMA-assisted therapy is the most researched psychedelic treatment and was closest to FDA approval. The Mithoefer protocol combines non-directive, trust-based support with MDMA's pharmacological effects. The FDA advisory committee raised concerns about methodology and blinding — the field is still navigating this.
-
Psilocybin Research
Johns Hopkins (Griffiths), Imperial College London (Carhart-Harris), and NYU (Ross) led the psilocybin renaissance. Griffiths's 2006 study on mystical experience in healthy volunteers was the landmark. Subsequent trials for depression, end-of-life distress, addiction, and OCD have shown remarkable results.
Concepts: Mystical-type experience · Ego dissolution · Psychological flexibility · Default mode network disruption · Entropic brain hypothesis · Emotional breakthrough
Relation: Carhart-Harris's "entropic brain hypothesis" provides the leading neuroscientific model: psychedelics increase neural entropy, disrupting rigid patterns (the default mode network) and allowing new configurations. This may explain both the subjective experience and the therapeutic mechanism.
-
Ketamine-Assisted Psychotherapy
Ketamine — an anesthetic already legal and widely used — became the first legally available psychedelic-adjacent therapy. KAP combines sub-anesthetic ketamine with psychotherapeutic support. Different from IV ketamine clinics (which focus on pharmacology without therapy).
Concepts: Dissociative state · NMDA receptor antagonism · Neuroplasticity window · Psychotherapeutic integration · Intention setting
Relation: KAP occupies a unique position: it's legally available now, doesn't require special regulatory approval, and provides a dissociative rather than classical psychedelic experience. It's both a treatment in its own right and a training ground for therapists preparing for psilocybin and MDMA.
-
Integration & Harm Reduction
Integration — the process of making meaning of psychedelic experiences and incorporating insights into daily life — is increasingly recognized as the therapeutic core. PHRI (Psychedelic Harm Reduction & Integration) provides support for people who have had difficult psychedelic experiences. Fireside Project offers a peer support line for people during or after psychedelic experiences.
Concepts: Integration · Difficult experiences (not "bad trips") · Harm reduction · Spiritual emergency · Preparation, experience, integration
Relation: The recognition that the experience itself is not the therapy — integration is — echoes Janet's phase model and Herman's reconnection stage. The psychedelic experience opens a door; integration determines whether the person walks through it. PSIP takes a different position: the therapeutic work happens during the medicine state itself through active relational engagement with somatic defense cascades, not primarily through post-session integration.
-
EMBARK
A transdiagnostic, pan-psychedelic clinical framework. Six domains: Existential-Spiritual, Mindfulness, Body-Aware, Relational, Keeping Momentum, and Awareness. Designed to be adaptable across substances and clinical populations. Developed for the NYU psilocybin trials.
Concepts: Six clinical domains · Pan-psychedelic framework · Transdiagnostic · Preparation → medicine session → integration · Therapist competencies
Relation: EMBARK represents the field's move toward manualized, trainable frameworks. It integrates elements from multiple therapeutic traditions (existential, somatic, relational, mindfulness) into a coherent model for psychedelic-assisted therapy.